It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in ...

The research team led by Professor Jongmin Kim from the Department of Life Sciences at POSTECH, along with graduate students ...

The Uttar Pradesh government is running a campaign to eliminate tuberculosis (TB) from the state by 2025. Over 27 lakh ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Exicure ( (XCUR) ) has provided an update.

Researchers have developed a new technology that improves the precision and integration density of synthetic genetic circuits.

Researchers have successfully developed a modular synthetic translational coupling element (SynTCE), significantly enhancing ...

The hope of the study is that this improved genetic knowledge will aid the development of synthetic therapies to treat or ...

To develop RNA medicines targeting a proprietary bundle of tumor antigens, Epitopea is tapping nucleic acid delivery ...

Enver Cagri Izgu, from the School of Arts and Sciences at Rutgers-New Brunswick, and his team will use a nearly $2 million ...

Osteoporosis, characterized by an imbalance in bone remodeling, is a growing health concern worldwide. Previous research has ...

In spite of intensive research, glioblastoma remains one of the most lethal types of brain cancer. Temozolomide (TMZ) is used ...